<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7033915/results/search/test_trace/results.xml">
  <result pre="that the work is properly cited. For commercial re-use, please" exact="contact" post="journals.permissions@oup.comofaa040.pdf Abstract Abstract Background With the introduction of direct-acting"/>
  <result pre="pump inhibitors, metamizole, statins, and carvedilol. Conclusions DDIs during antiviral" exact="treatment" post="still affect about 40% of HCV patients. The lower"/>
  <result pre="direct-acting antivirals (DAAs) drug–drug interactions (DDIs) hepatitis C virus (HCV)" exact="infection" post="patient characteristics polypharmacy Funding German Center for Infection Research10.13039/100009139"/>
  <result pre="million people worldwide suffered from chronic hepatitis C virus (HCV)" exact="infection" post="[1]. Currently the World Health Organization (WHO) is calling"/>
  <result pre="and many of those with mild disease chose to defer" exact="treatment" post="[7–9]. Furthermore, drug–drug interactions (DDIs) emerged as a new"/>
  <result pre="(SOF) in January 2014 allowed for IFN-free therapy, which facilitated" exact="treatment" post="eligibility [14]. In 2014–2015, the first fixed-dose combination of"/>
  <result pre="failures [24–30]. Until now, almost all previous limitations of HCV" exact="treatment" post="have been overcome. Currently available DAA regimens achieve SVR"/>
  <result pre="well tolerated [24–30]. It is widely believed that with today’s" exact="treatment" post="options the risk for DDI via, for example, CYP"/>
  <result pre="expected that the diversity of HCV patients who receive antiviral" exact="treatment" post="has increased over the last years. This includes patients"/>
  <result pre="population. METHODS Cohort Overall, 668 consecutive patients with chronic HCV" exact="infection" post="who were treated with a DAA regimen at the"/>
  <result pre="Assessment of Baseline Characteristics and Patients’ Regular Outpatient Medications Laboratory" exact="testing" post="for albumin, bilirubin, and quick/international normalized ratio (INR) was"/>
  <result pre="In some cases, the regular outpatient medication was modified before" exact="treatment" post="due to the risk of DDI with the selected"/>
  <result pre="cohort and each individual antiviral that was available for the" exact="treatment" post="of HCV infection in the last decade. Administration of"/>
  <result pre="individual antiviral that was available for the treatment of HCV" exact="infection" post="in the last decade. Administration of a fixed-dose combination"/>
  <result pre="ribavirin (RBV). 2. Real-world incidence of DDIs due to antiviral" exact="treatment" post="DDIs were assessed between the actual regular outpatient medication"/>
  <result pre="note, the frequency of cirrhosis among the patients receiving antiviral" exact="treatment" post="declined significantly over the years (A: 80.2%, B: 44.1%,"/>
  <result pre="DDIs that might occur in case of coadministration. Among all" exact="treatment" post="regimens, the combination of OBV/PTV/r and BOC (alone) showed"/>
  <result pre="time periods in detail, it became obvious that in every" exact="treatment" post="period DAAs with a considerable potential for DDIs were"/>
  <result pre="from the cohort. Abbreviation: PEG-IFN, pegylated interferon. Compared with previous" exact="treatment" post="periods, the current most-used regimens, GLE/PIB, ELB/GRZ, VEL/SOF ± VOX, did"/>
  <result pre="the metabolism of the antivirals and risk the efficacy of" exact="treatment" post="when coadministered. Real-World Incidence of Drug–Drug Interactions due to"/>
  <result pre="a new challenge with the approval of DAAs for the" exact="treatment" post="of HCV infection [11]. Although this work for the"/>
  <result pre="with the approval of DAAs for the treatment of HCV" exact="infection" post="[11]. Although this work for the first time provides"/>
  <result pre="the real-world analysis remained more or less stable over the" exact="treatment" post="periods, with about 40% of HCV patients affected. Advantages"/>
  <result pre="change in the epidemiology of HCV patients, mainly due to" exact="treatment" post="eligibility and expansion [1, 14, 33]. Some of these"/>
  <result pre="that HCV patients’ characteristics have indeed changed during the different" exact="treatment" post="periods. The frequency of treated patients with cirrhosis has"/>
  <result pre="increased. One may assume that this is a result of" exact="treatment" post="policy over the last years. Patients with advanced stages"/>
  <result pre="of these patients were infected before the introduction of anti-HCV" exact="testing" post="in the early 1990s. However, the most complicated cases"/>
  <result pre="immunosuppressive drugs, we recorded a significant increase due to new" exact="treatment" post="options for renal transplant recipients (ie, glecaprevir/pibrentasvir and elbasvir/grazoprevir)."/>
  <result pre="for renal transplant recipients (ie, glecaprevir/pibrentasvir and elbasvir/grazoprevir). The excellent" exact="treatment" post="options available started an intensive debate about the use"/>
  <result pre="donor organs for HCV-negative recipients. It seems likely that the" exact="treatment" post="of transplant recipients may remain particularly relevant in the"/>
  <result pre="well as the most relevant drugs and mechanisms involved. Unrestricted" exact="treatment" post="of high-risk populations like PWID will require general considerations"/>
  <result pre="WelschC, et al.The efficacy and safety of direct acting antiviral" exact="treatment" post="and clinical significance of drug-drug interactions in elderly patients"/>
  <result pre="potential drug-drug interactions in patients with chronic hepatitis C viral" exact="infection" post="undergoing antiviral therapy with interferon-free DAAs in the PITER"/>
  <result pre="treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1" exact="infection" post="and stage 4-5 chronic kidney disease (the C-SURFER study):"/>
  <result pre="and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus" exact="infection" post="and compensated cirrhosis: an integrated analysis. Gastroenterology2017; 152:1372–1382.e2.28193518 28.FosterGR,"/>
  <result pre="for the Study of the Liver (EASL). EASL recommendations on" exact="treatment" post="of hepatitis C 2018. J Hepatol2018; 69:461–511.29650333 32.Friedrich-RustM, OngMF,"/>
  <result pre="1):1–5. 34.KittnerJM, WeissNM, WiltinkJ, et al.Defer or treat? Reasons for" exact="treatment" post="decisions in patients with chronic hepatitis C genotype 1"/>
  <result pre="FlammSL, et al.collab: SOLAR-1 InvestigatorsLedipasvir and sofosbuvir plus ribavirin for" exact="treatment" post="of HCV infection in patients with advanced liver disease."/>
  <result pre="SOLAR-1 InvestigatorsLedipasvir and sofosbuvir plus ribavirin for treatment of HCV" exact="infection" post="in patients with advanced liver disease. Gastroenterology2015; 149:649–59.25985734 36.MannsM,"/>
  <result pre="in patients with genotype 1 or 4 hepatitis C virus" exact="infection" post="and advanced liver disease: a multicentre, open-label, randomised, phase"/>
  <result pre="trial. Lancet Infect Dis2016; 16:685–97.26907736 37.ReauN, KwoPY, RheeS, et al.Glecaprevir/pibrentasvir" exact="treatment" post="in liver or kidney transplant patients with hepatitis C"/>
  <result pre="drug interactions of medications used to treat hepatitis C virus" exact="infection" post="in the setting of chronic kidney disease and kidney"/>
 </snippets>
</snippetsTree>
